NCT05305287View on ClinicalTrials.gov

Quantifying Hepatic Mitochondrial Fluxes in Humans

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Non-Alcoholic Fatty Liver DiseaseType 2 DiabetesMitochondrial Metabolism Disorders
Interventions
DRUG

Pioglitazone

An insulin sensitizer and anti-diabetic agent. Participants will be started on 15 mg/day, increased to 30 mg/day at week 2 and then to 45 mg/day at week 4.

OTHER

Placebo

Placebo for pioglitazone

Trial Locations (2)

78207

RECRUITING

Texas Diabetes Institute - University Health System, San Antonio

78229

RECRUITING

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER